Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: cm who wrote (795)	5/25/1999 10:10:00 PM
From: Ariella	Respond to of 1386

I will be "short" on stories, I'm afraid, as my confidentiality agreement reaches past the formal relationship. But I can tell you that I worked closely with the CFO, COO and new head of IR, had a lengthy, very intense discussion with the CEO when he was recently in the US and also had several communications with the VP of Development in Israel. These people are bright and they work very, very hard. Some of the comments posted on the threads -- like suggestions that someone suggest to management that HU-211 might be a fast track candidate -- are kind of funny. People should credit the management with more brains! It's a foregone conclusion that PARS and partner would request fast track status for that drug. I have an extra moment now to share something from the annual -- Aside from tamoxifen, PARS has a second hormonal EMS (enhanced molecular structure) project: page 14 <<Pharmos is also exploring novel antagonists and agonists of testosterone for the treatment of prostate cancer, hair loss, and male hypogonadism. Over 300,000 new cases of prostate cancer are diagnosed in the US. alone each year and an estimated 40 million Americans suffer from some degree of hereditary hair loss. Early attention to male hypogonadism has been directed at its role in sexual dysfunction, but new research suggests it plays a part in such disorders as osteoporosis, depression, glucose intolerance, and anemia, any of which would significantly widen the number of potential patients who might benefit from new treatments.>> Money is needed from the HU-211 partnership to gear up the research in this project. As for HU-211, one of my favorite lines from the annual comes from the Chairman/CEO's letter: <<We are confident that the clinical profiles of our products and their competitive edge will enable us to attract a strong marketing partner for dexanabinol as well as for technologies commercialized in the future.>> Anyone who knows the management of this company well knows their tendency is to speak modestly about themselves and their work. The voice of the annual has a confidence level that is quite remarkable in that context. Ariella